Vienna group makes vaccine headway in toxic shock syndrome


Decades after the condition was first documented in the 1980s, researchers say they have made the world’s first vaccine for toxic shock syndrome. In an early study, the vaccine--developed from detoxified Staphylococcus--was found to be safe and effective.

A joint effort between staff at the Medical University of Vienna’s Department of Clinical Pharmacology and the Vienna biopharma Biomedizinische Forschungsgesellschaft mbH tested the experimental vaccine in 46 young men and women. Phase I results demonstrated that the vaccine has “practically no side effects,” according to the team’s statement. When injected into skin, the vaccine induces the production of antibodies that kick into gear upon detecting a risk, the team said.

Bernd Jilma, an associate professor at MedUni Vienna, said the vaccine's interaction with the body is similar to a tetanus vaccination, explaining the immunization “lasts for 5 years or more.”


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

A life-threatening complication of infection by S. aureus or group A streptococcus bacteria, TSS has typically been connected with use of superabsorbent tampons, according to Mayo Clinic. Symptoms include high fever, vomiting, low blood pressure or a rash. Though very rare, it can lead to organ failure and impact anyone.

"Nevertheless, in 50% of cases the disease is associated with menstruation in young women," Jilma said in the statement. Those with a compromised immune system stand at a greater risk, and so could be “preventively vaccinated,” the team concluded.

Next up is a Phase II trial, which the group says is underway and seeking volunteers. The vaccine is “some years” away from clinical use, Biomedizinische Forschungsgesellscaft mbH director Martha Eibl said in the release.

The Phase I results were published in The Lancet Infectious Diseases.

- here’s the release
- and the abstract

Related Articles:
Expect vaccines market to swell to $40B by 2020: Tufts CSDD
Astellas, ClearPath launch vaccines firm aimed at healthcare-associated infections


Suggested Articles

How is regulatory evolving to keep up with the digital innovation surge and consumer expectations? How can stakeholders wok better together?

Perrigo is treading water in its specialty drugs reinvention plan. Could a merger with another struggling drugmaker—à la Pfizer and Mylan—be the cure?

Companies routinely update analysts, but a new SEC order for tiny TherapeuticsMD offers a lesson—or reminder—about when to keep quiet.